CREATE Medicines Receives Approval to Initiate First-in-Human Phase 1/2 Clinical Trial of In Vivo CAR-T Candidate CRT-402 for Autoimmune Diseases
Australian HREC approval clears the initiation of CREATE's first-in-human Phase 1/2 study evaluating CRT-402 in patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIM). HREC approval represents the final regulatory step...
Australian HREC approval clears the initiation of CREATE's first-in-human Phase 1/2 study evaluating CRT-402 in patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIM). HREC approval represents the final regulatory step...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.